SG
VERA icon

Sankala Group’s Vera Therapeutics VERA Stock Holding History

Sankala Group’s Portfolio VERA Stock Details VERA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.96K Hold
61
– – ﹤0.01% 517
2026
Q1 		$2.38K Hold
61
– – ﹤0.01% 478
2025
Q4 		$2.49K Buy
+61
New +$2.17K ﹤0.01% 486

Other funds holding VERA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Sankala Group's VERA Position: Q2 2026 in Review

Sankala Group held its Vera Therapeutics (VERA) position steady in Q2 2026 at 61 shares worth $1.96K. The position accounts for ﹤0.01% of the portfolio, ranked #517.

Sankala Group first reported a position in VERA in Q4 2025 and has held it in 3 quarters since. The position peaked at $2.49K in Q4 2025. 219 funds tracked by Wall St. Rank hold VERA as of Q2 2026.

  • Sankala Group held 61 shares of Vera Therapeutics worth $1.96K as of Q2 2026.
  • Sankala Group left its Vera Therapeutics share count unchanged in Q2 2026.
  • Vera Therapeutics made up ﹤0.01% of Sankala Group's portfolio in Q2 2026, its #517 holding.
  • Sankala Group first reported a position in Vera Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • Sankala Group's Vera Therapeutics position peaked at $2.49K in Q4 2025.
  • 219 funds tracked by Wall St. Rank held Vera Therapeutics as of Q2 2026.

Based on Sankala Group's 13F filing for Q2 2026, filed 18 Aug 2026.